Results Informative oncological associations included 1) thymoma in 85% of patients with muscle striational, acetylcholine receptor antibodies plus CRMP5 autoantibodies; 2) lung carcinoma in 80% with both P/Q-type and N-type calcium channel antibodies plus SOX1-IgG; 3) in men, prostate carcinoma frequency more than doubled when striational and muscle AChR specificities were accompanied by ganglionic AChR antibody. In women, amphiphysin-IgG alone was associated commonly with breast carcinoma, but amphiphysin-IgG coexisting with ANNA-1 or CRMP5-IgG, was associated with lung cancer (p<0.0001). In the validation cohorts, many tumor-associated profiles were encountered that matched the clusters identified in the screening study (for example 15% of thymoma patients had striational, acetylcholine receptor antibodies plus CRMP5 autoantibodies).
Introduction
Autoimmune neurology is a rapidly evolving clinical subspecialty. Neural-specific autoantibodies serve as diagnostic and prognostic biomarkers and guide therapy. Defined autoantigens include intracellular proteins (nuclear [3] [4] [5] [6] [7] and cytoplasmic enzymes, [8] [9] [10] transcription factors and RNA binding proteins) and plasma membrane or secreted proteins [11] [12] [13] (neurotransmitter receptors, ion channels, ion channel-complex components and water channels). Molecular identification of neural autoantigens has yielded insight into pathogenic mechanisms underlying neurological autoimmunity. For example, some disorders are mediated by IgG binding to extracellular epitopes of plasmalemmal proteins and others by cytotoxic T cells specific for peptides derived from the intracellular antigens. 14 Manifestations of neurological autoimmunity are often protean, extending beyond the scope of text book "syndromic" descriptions. For example, the antineuronal nuclear autoantibody-type 1 (ANNA-1 or "anti-Hu") is not restricted to sensory neuronopathy (the "Hu syndrome") or limbic encephalitis. ANNA-1 is commonly associated with gastrointestinal dysmotility, sensorimotor neuropathy or other neurological manifestations. 3 It is unusual for paraneoplastic neurological autoimmunity to target a single autoantigen. As a neoplasm evolves, neoantigens may appear as part of the mutagenic process. Upregulated self proteins expressing "foreign" epitopes could bypass self-tolerized T cells when exposed to the immune system as 
Statistical methods
The observed frequencies of antibody clusters were compared to hypothesized frequencies.
Hypothesized frequencies for clusters of two or three autoantibodies were calculated under a conditional independence assumption (as if the cluster occurred by chance) and were compared with the observed frequencies (appendix). Data for 15 antibodies of interest were available for analysis in all the the 78,889 patients with. We reviewed the clinical records of patients with clusters whose observed frequencies far outnumbered hypothesized frequencies. We restricted the clinical analysis to clusters for which clinical information was available for at least five patients. In the validation study, the frequencies of individual neural autoantibodies and their clusters in each cancer type were compared with tumor-specific profiles identified in the initial mathematical phase of analysis. Horta et al. -8- Comparisons of clinical variables between groups were made using Chi-square and Fisher's exact test where appropriate. All analyses were conducted using SAS version 9 (Cary, NC) and JMP 9.0.1.
Results
Of the 78,889 patients tested, 9,183 (12%) had one or more neural autoantibodies: 7,592 (83%) had only one, 1,316 (14% ) had two, 213 (2.3%) had three, 52 (0.57%) had four, 9 (0.1%) had five and 1 (0.01%) had six. These observed frequencies exceed the frequencies hypothesized if clustering of autoantibodies occurred only by chance: 1,316 patients were observed with 2 neural autoantibodies, compared with 365 expected by chance; 213 patients were observed with 3 neural autoantibodies, compared with 10 expected by chance ; 62 patients were observed four or more autoantibodies, compared with 0 expected by chance. For each neural autoantibody tested, its frequency and the frequency of the 3 most common coexisting autoantibodies (first, second and third) are shown in table 1.
Clusters of 2 neural autoantibodies ("duo clusters"):
The observed versus hypothesized frequencies for clusters of two neural autoantibodies are illustrated in figure 1a. Duo clusters in which the observed frequencies most exceeded the hypothesized frequencies were: muscle AChR and striational (535 vs 46), N-type VGCC and P/Q-type VGCC (150 vs 6) and VGKC-complex and striational (129 vs 67). Horta et al. -9- P/Q-type VGCC (17% vs 1% of all clusters in which ANNA-1 is one of the duo), ANNA-1 and CRMP5 (34% vs 1% of all clusters in which ANNA-1 is one of the duo), SOX1 and P/Q-type VGCC (60% vs 8% of all clusters in which SOX1 is one of the duo), SOX1 and N-type VGCC (30% vs 8% of all clusters in which SOX1 is one of the duo), amphiphysin and P/Q-type VGCC (27% vs 7% of all clusters in which amphiphysin is one of the duo), amphiphysin and ANNA-1 (36% vs 3% of all clusters in which amphiphysin is one of the duo), amphiphysin and CRMP5 (9% vs 1% of all clusters in which amphiphysin is one of the duo), PCA-2 and ANNA-1 (27% vs 3% of all clusters in which PCA-2 is one of the duo), PCA-2 and CRMP5 (27% vs 1% of all clusters in which PCA-2 is one of the duo), N-type VGCC and P/Q-type VGCC (60% vs 10% of all clusters in which N-type VGCC is one of the duo).
Clusters of 3 neural autoantibodies ("trio clusters") or more:
The observed versus hypothesized frequencies for clusters of three neural autoantibodies are illustrated in figure 2. The observed frequencies most exceeded the hypothesized frequencies for the following trio clusters: muscle AChR, striational plus ganglionic AChR (83 vs 1); muscle AChR, striational plus VGKC-complex (20 vs 1); VGKC-complex, N-type VGCC plus P/Q-type VGCC (18 vs 0); striational, N-type VGCC plus P/Q-type VGCC (13 vs 0); muscle AChR, striational plus CRMP5 (7 vs 0); VGKC-complex, striational plus P/Q-type VGCC (6 vs 1); muscle AChR, N-type VGCC plus P/Q-type VGCC (6 vs 0); SOX1, N-type VGCC plus P/Qtype VGCC (5 vs 0). Interestingly, all of these trio clusters arose from the addition of a third autoantibody to the duo clusters that we identified as having an observed frequency exceeding the hypothesized frequency. Results for clusters of four (52 patients) and five (9 patients) neural autoantibodies are shown in supplemental tables 1 and 2 (Appendix).
Clinical implications of neural autoantibody clusters:
This analysis was restricted to the clusters identified in Figures 1 and 2 .
Muscle AChR and striational autoantibodies ( Table 2 ): This duo cluster was associated with a tumor diagnosis in 45% of patients. The association with cancer was more frequent and more type-specific when this duo was combined with a third neural autoantibody. For a trio cluster with ganglionic AChR, the cancer frequency was 67%; with CRMP5 or VGKC-complex autoantibodies the cancer frequency was 81%. As an illustration of tumor specificity, with VGKC-complex or CRMP5 as the third autoantibody, the frequency of thymoma as the associated cancer rose from 36% to 85%, (p<0.004). Male sex predominated when ganglionic AChR was the third autoantibody (p = 0.0004 compared to 31267 seronegative patients), and the frequency of prostate cancer rose by 30% (p=0.0443). Prostate carcinoma was the most common cancer associated with this trio. Lung cancer also was encountered with the muscle AChR and striational duo cluster but not when a third autoantibody was associated.
N-type VGCC and P/Q-type VGCC, Table 2 : The duo cluster N-type VGCC and P/Q-type VGCC was associated with Lambert-Eaton syndrome most commonly in a trio combination with SOX1 (6% vs 30%). This trio was associated more highly with lung cancer than the cluster Ntype VGCC and P/Q-type VGCC alone (p=0.002) or with trio clusters that included VGKCcomplex, striational plus muscle AChR. -11- syndrome and cancer was found in less than 25% of cases. In contrast, when muscle AChR coexisted with the duo cluster striational and VGKC-complex, 78% of patients had myasthenia gravis (p<0.0001). This trio cluster was highly associated with thymoma (p=0.008). . In this study, amphiphysin-IgG was detected in 7 male patients; the 4 for whom histories were available all had small-cell lung carcinoma regardless of coexisting autoantibodies. Cancer was diagnosed in 31 of 37 women who had amphiphysin-IgG without a coexisting autoantibody, 31 had cancer (84%). Lung cancer accounted for only 26% of those cancers; 61% had breast cancer. However, when amphiphysin-IgG was accompanied by ANNA-1 or CRMP5 the frequency of lung cancer was 94% (p < 0.0001); only 1 patient had breast cancer (6%, p = 0.0004). Table 3 : Among 155 ANNA-1-seropositive patients for whom clinical information was available, cancer was identified more frequently when ANNA-1-IgG coexisted with P/Q-type VGCC or CRMP5-IgG than when ANNA-1 occurred alone (79% vs 58%, p = 0.02, Table 3 ). The coexistence of P/Q-type VGCC or CRMP5-IgG with ANNA-1 increased the likelihood of small-cell carcinoma from 83% (with ANNA-1 alone, 55 of 65 patients) to 100% (34 of 34 patients with accompanying P/Q-type VGCC or CRMP5, p = 0.01). Other tumor types encountered in 10 patients with ANNA-1 alone included breast carcinoma (1), neuroblastoma (4), non-Hodgkin lymphoma (1), uterine carcinoma (1), basal cell skin carcinoma (2), neuroendocrine (non-specified, 1). 
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Tumor Validation
This phase of the study comprised patients with a histologically proven tumor without neurological symptoms: 33 with thymoma, 240 with lung carcinoma (30 small-cell and 210 nonsmall-cell) and 30 with tonsil carcinoma. We additionally tested 61 patients who had thymoma and a paraneoplastic neurological syndrome. All were tested for the same 15 autoantibodies as in the screening phase of the study. The frequency of the most commonly encountered neural autoantibodies is shown for each group in table 4. The tonsil carcinoma group lacked neural autoantibodies except for a single patient seropositive for striational antibody. However, neural autoantibodies were frequent in sera of the thymoma and lung carcinoma groups, and even more frequent in thymoma patients with a neurological paraneoplastic syndrome. As observed in the screening phase, striational, muscle AChR, VGKC and CRMP5 IgGs were commonly encountered in thymoma (≥10%). Muscle AChR and striational antibodies were commonly observed in both thymoma groups but were more frequent in patients with thymoma and neurological syndromes than patients with thymoma and non neurological syndromes (p<0.002).
VGCC (N or P/Q type) antibodies were encountered in 6% of lung carcinoma patients. ANNA-1 was encountered in 10% of patients with small-cell lung carcinoma but in 0% of those with nonsmall-cell carcinoma (p=0.007). Table 4 illustrates the frequency of neural antibodies occurring alone, or in duos, trios and groups of 4 or more for each cancer group. Clustering of neural autoantibodies was common with thymoma patients (69% had clusters of 2 or more antibodies, no significant difference between those with and without neurological symptoms). For lung carcinoma patients, clustering of 2 or more antibodies was observed in 22% of sera. Horta et al. -13- The most common duo in both thymoma groups was muscle AChR and striational antibodies (accounting for 89% of duos encountered in that group). This duo was the most commonly observed cluster in the screening phase and was more strongly associated with thymoma than lung cancer. Muscle AChR with striational and CRMP5 followed by muscle AChR with striational and VGKC were the most commonly encountered trios in both thymoma cohorts (none were observed in the other cancer cohorts). These trios were identified in the screening phase of the project as having a much higher observed than hypothesized frequency.
In the screening phase, thymoma accounted for 85% of tumors identified in patients seropositive for these trios.
Two duos were more frequent in lung cancer: N -type VGCC and P/Q-type VGCC ; Ntype VGCC and ganglionic AChR. The most common trio in the lung cancer cohort was N-type VGCC, P/Q-type VGCC plus CRMP5. Neither of these duos or trios were observed in the other cancer cohorts. In the screening phase, lung carcinoma accounted for 13% of tumors identified in patients seropositive for the duo N-type VGCC and P/Q-type VGCC and none of the patients with this duo or combinations of VGCC and CRMP5 had thymoma.
Discussion/Conclusion
The clustering of onconeural autoantibodies revealed in the mathematical phase of this study was confirmed in the separate cancer validation study, and supports and extends previous clinical observations. These results implicate multi-molecular tumor-derived antigenic -14- autoantibody evaluation rather than testing for single antibodies permits the identification of such clusters.
Recognition of autoantibody clusters increases the likelihood of cancer detection. In our study we found that the frequency of cancer was higher when ANNA-1-IgG coexisted with CRMP5-IgG or VGKC-complex-IgG than when occurring alone. Similar findings were reported by a Honnorat et al who reported that the frequency of cancer with ANNA-1 and CRMP-5-IgG alone was 77% and 86%, respectively, but > 90% when occurring together. 14 In our cancer validation study we found that clusters of 2 or more neural autoantibodies occur in a majority of patients with thymoma and are not uncommon in lung carcinoma patients (especially small-cell carcinoma). Autoantibodies that are recognized accompaniments of lung carcinoma tended to cluster more frequently than hypothesized both as a duo (N-type VGCC and P/Q-type VGCC) and as a trio (N-type VGCC, P/Q-type VGCC and SOX1). 3, 6, 11 The addition of SOX1 antibodies to the duo N-type VGCC and P/Q-type VGCC increased the frequency of small-cell carcinoma from Horta et al. -15- 13% to 86%. Similarly, autoantibodies recognized as accompaniments of thymoma tended to cluster as the duo muscle AChR and striational and as the trio muscle AChR, striational and CRMP5. 9, 16, 17 The findings of this study do not support the traditional concept that P/Q-type VGCC coexisting with N-type VGCC autoantibodies is necessarily associated with Lambert-Eaton syndrome, and muscle AChR and striational antibodies are synonymous with myasthenia gravis.
When tested in the context of a paraneoplastic evaluation, cancer was found in one third of 47 patients with both P/Q-type VGCC and N-type VGCC (6% lung cancer); only three of those 47 patients had evidence of Lambert-Eaton syndrome. Similarly less than 70% of patients with muscle AChR and striational antibodies had a diagnosis of myasthenia gravis. Autoantibody specificities: ANNA-1, ANNA-2 and ANNA-3 = anti-neuronal nuclear, types 1, 2 and 3; CRMP5 = collapsin response-mediator protein-5; gAChR and mAChR = ganglionic-type and muscle-type 
